Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 27Observational 6Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 9Pancreatic Neoplasms 5Sarcoma 4Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Melanoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Uterine Neoplasms 2Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma, Ewing 1Primary Myelofibrosis 1PSR Ovarian Cancer With a BRCA Mutation 1Ovarian Diseases 1Osteosarcoma 1Neurofibrosarcoma 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Ovarian Diseases × Gynecologic × Clear all
NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing
Gynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡